859 / 1138
Promising results in all risk groups but FU still short
Very few patients in the high-risk group and no further information about
detailed risk
Multi-center analysis:
King et al Radiat Oncol 2013
Risk-group Follow-
up
Low
36 mo
Intermediate 31 mo
High
23 mo
1100 patients
8 institutions
All patients enrolled in
phase II studies
34
ESTRO SBRT Course 2014 - Emerging SBRT indications
SBRT for prostate cancer